Navigation Links
Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
Date:8/14/2008

alatin, please visit Palatin Technologies' website at http://www.palatin.com

Forward-looking Statements

Statements about the Company's future expectations, including statements about its development programs, proposed indications for its product candidates, pre-clinical activities, clinical activities, marketing collaborations, and all other statements in this document other than historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and as that term is defined in the Private Securities Litigation Reform Act of 1995. The Company intends that such forward-looking statements shall be subject to the safe harbors created thereby. Palatin's actual results may differ materially from those discussed in the forward- looking statements for various reasons, including, but not limited to the Company's ability to fund development of its technology, ability to establish and successfully complete clinical trials and pre-clinical studies and the results of those trials and studies, dependence on its partners for certain development activities, need for regulatory approvals and commercial acceptance of its products, ability to recommence marketing and gain commercial acceptance of NeutroSpec(R), ability to protect its intellectual property, and other factors discussed in the Company's periodic filings with the Securities and Exchange Commission. The Company is not responsible for updating for events that occur after the date of this press release.


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
2. Palatin Technologies Refutes Competitive Technologies Contention of Material Breach
3. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
4. Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007
5. Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007
6. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
7. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
8. Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
9. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Axovant Sciences Ltd. (NYSE:  AXON), a leading clinical-stage ... upcoming presentations at three investor conferences: , Wednesday, ... Conference in New York at the ... 2:00 PM at the BioCentury NewsMakers Conference in ... Conference Center , Thursday, September 17 at 9:30 AM ...
(Date:9/2/2015)... Florida (PRWEB) , ... September 02, 2015 , ... ... been treated and managed with the use of special anti-vascular endothelial growth factor ... in many more patients, currently does not have a scientific protocol for the ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... development of botanical and plant-derived compounds. BCC Research reveals in its new ... 2020 because this market defines the category and generates the most market demand. ...
(Date:9/2/2015)... 2015 BioLight Life Sciences ... "Company"), a firm that invests in, manages and ... announced today that presentations highlighting its IOPtiMate™ system ... at the Ophthalmology Futures European Forum and the ... & Refractive Surgeons ("ESCRS"), both taking place in ...
Breaking Biology Technology:Axovant Sciences To Present At Upcoming Investor Conferences 2Axovant Sciences To Present At Upcoming Investor Conferences 3StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3
... Life Sciences Industry in ... Western ... (PLSG), the organization providing capital investments and,customized company formation and ... the PLSG has reached a,significant milestone with over $10 million ...
... Huifeng,Bio-Pharmaceutical Technology, Inc. (OTC Bulletin Board: HFGB), ... and pharmaceutical raw materials,for use in pharmaceutical, ... will release financial results for their first ... 2008, after the US markets close.,Huifeng,s earnings ...
... Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: NTII ), ... from Merz Pharmaceuticals GmbH (Merz) for sales,by ... for the treatment of,moderate-to-severe Alzheimer,s disease during ... exclusive marketing agreement, NTI currently receives,quarterly royalty ...
Cached Biology Technology:The Pittsburgh Life Sciences Greenhouse Tops $10M in Company Investments 2The Pittsburgh Life Sciences Greenhouse Tops $10M in Company Investments 3
(Date:8/24/2015)... Calif. , Aug. 24, 2015  Based on its ... recognizes DERMALOG with the 2015 African Biometrics Company of the ... has achieved substantial commercial success in Africa ... , where it has implemented one of the largest ... banks as well as the Central Bank of ...
(Date:8/18/2015)... , Aug. 18, 2015  Navitas ... key contributor to the Submission Content Management ... IRISS, a non-profit forum. Dedicated to the Implementation ... a neutral platform for industry, vendors, health ... information and work towards a standard method ...
(Date:8/12/2015)... , Aug. 12, 2015  New research ... can attack Android phones to steal users, fingerprints. ... increasing availability of fingerprint scanners on mobile devices, ... concern. To secure biometrics on mobile devices, HYPR ... augment these convenient authentication systems with strong cryptographic ...
Breaking Biology News(10 mins):Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 2Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 3Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 4Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 5Frost & Sullivan Applauds DERMALOG's Rise as the Supplier of Best-in-class Biometric Solutions in Africa 6Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3
... of the Blackleg fungus, which causes the most damaging disease ... time by a team of French and Australian scientists. ... University of Melbourne, who led the Australian research team, said ... Blackleg disease. "The 12,500 genes that constitute the genetic ...
... Optiqua Technologies Pte Ltd is collaborating with Nanyang ... in biomolecular sciences and sensor technology. Optiqua, ... provides the international water industry with innovative products ... detection of contaminants in water. The sensor technology ...
... , Scientists today agree that there are five molecules that ... an estimated five million Americans. The potency of these molecules ... Prof. Daniel Michaelson of Tel Aviv University,s Department ... Sciences has illuminating news about one of these five molecules ...
Cached Biology News:Uncovering the genome secrets of the Blackleg fungus 2Optiqua-NTU partnership to develop next-generation sensor technology 2Good diets fight bad Alzheimer's genes 2
... FastPlax Titer Kit is designed for determination of ... 46 days as in other methods. Classical determination ... of plaques, but the FastPlax Kit takes advantage ... gp64 glycoprotein on the cell surface as early ...
... software for all your biopharmaceutical applications needs. ... single, scalable software package. The graphical user ... control of all Freedom instruments from simple ... with one liquid handling arm up to ...
... an advanced system for isolating DNA from agarose gels ... directly for any downstream application. Features ... in 56 minutes Low melting point agarose not ... gels No specialised equipment required DNA is ...
... incubators with rotators. Graduated, 35 mm ... plug-seal screw-cap with O-ring for a ... to accept different size hybridization membranes. ... separately. • Comp Dim: tube L ...
Biology Products: